Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

57.28USD
15 Nov 2019
Change (% chg)

$-0.61 (-1.05%)
Prev Close
$57.89
Open
$57.54
Day's High
$57.75
Day's Low
$57.25
Volume
587,831
Avg. Vol
397,620
52-wk High
$58.01
52-wk Low
$43.12

Latest Key Developments (Source: Significant Developments)

Bluebird Bio, Novo Nordisk In Research Agreement To Develop Genome Editing Candidates For Haemophilia, Other Genetic Diseases
Wednesday, 9 Oct 2019 

Oct 9 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO AND NOVO NORDISK ENTER INTO RESEARCH AGREEMENT TO DEVELOP IN VIVO GENOME EDITING CANDIDATES FOR HAEMOPHILIA AND OTHER SEVERE GENETIC DISEASES.BLUEBIRD BIO INC - RESEARCH COLLABORATION IS FOR A TERM OF THREE-YEAR.  Full Article

Swift Health Systems Raises $45 Million In Series C Funding
Tuesday, 8 Oct 2019 

Oct 8 (Reuters) - SWIFT HEALTH SYSTEMS : :SWIFT HEALTH SYSTEMS RAISES $45 MILLION IN SERIES C FUNDING.SWIFT HEALTH SYSTEMS - FINANCING CO-LED BY VIVO CAPITAL, NOVO HOLDINGS AND VENBIO PARTNERS.SWIFT HEALTH SYSTEMS - NEW FUNDING ROUND BRINGS TOTAL CAPITAL RAISED TO MORE THAN $70 MILLION.  Full Article

Novo Nordisk To Price New Diabetes Pill At Level With Its Injectable Ozempic Drug
Monday, 23 Sep 2019 

Sept 23 (Reuters) - NOVO NORDISK'S CFO KARSTEN MUNK KNUDSEN SAYS ON CALL WITH INVESTORS: :LIST PRICE OF NEW ORAL DIABETES DRUG, RYBELSUS, WILL BE AT SIMILAR LEVEL AS INJECTABLE OZEMPIC DRUG.THE U.S. FOOD AND DRUG ADMINISTRATION ON FRIDAY APPROVED AN ORAL VERSION OF NOVO NORDISK'S DIABETES DRUG SEMAGLUTIDE.THE WORLD'S BIGGEST PRODUCER OF DIABETES DRUGS ALREADY SELLS AN INJECTABLE ONCE-WEEKLY VERSION OF SEMAGLUTIDE UNDER THE BRAND NAME OZEMPIC AT NEARLY $800 PER MONTH.  Full Article

Novo Nordisk Says FDA Approves Rybelsus, The First GLP-1 Analog Treatment Available In A Pill For Adults With Type 2 Diabetes
Friday, 20 Sep 2019 

Sept 20 (Reuters) - Novo Nordisk A/S ::FDA APPROVES RYBELSUS® (SEMAGLUTIDE), THE FIRST GLP-1 ANALOG TREATMENT AVAILABLE IN A PILL FOR ADULTS WITH TYPE 2 DIABETES.NOVO NORDISK - FDA STILL REVIEWING NDA FOR RYBELSUS TO REDUCE MAJOR ADVERSE CARDIOVASCULAR EVENTS RISK IN ADULTS WITH TYPE 2 DIABETES, ESTABLISHED CVD.NOVO NORDISK - FDA DECISION ON NDA FOR RYBELSUS FOR ADDITIONAL INDICATION TO REDUCE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS EXPECTED IN Q1 2020.  Full Article

FDA Approves First Oral GLP-1 Treatment For Type 2 Diabetes
Friday, 20 Sep 2019 

Sept 20 (Reuters) - U.S. Food and Drug Administration::FDA - APPROVED RYBELSUS (SEMAGLUTIDE) ORAL TABLETS TO IMPROVE CONTROL OF BLOOD SUGAR IN ADULT PATIENTS WITH TYPE 2 DIABETES, ALONG WITH DIET, EXERCISE.U.S. FDA - APPROVAL OF RYBELSUS WAS GRANTED TO NOVO NORDISK.U.S. FDA - PRESCRIBING INFORMATION FOR RYBELSUS INCLUDES A BOXED WARNING TO ADVISE ABOUT THE POTENTIAL INCREASED RISK OF THYROID C-CELL TUMORS.U.S. FDA - RYBELSUS PRESCRIBING INFORMATION INCLUDES BOXED WARNING TO ALSO ADVISE IT IS NOT RECOMMENDED AS FIRST CHOICE OF MEDICINE FOR TREATING DIABETES.  Full Article

Novo Nordisk: Tresiba Shows Lower Risk Of Hypoglycaemia And Lower HbA1c Compared To Insulin Glargine U300 In People With Type 2 Diabetes
Thursday, 19 Sep 2019 

Sept 19 (Reuters) - Novo Nordisk A/S ::TRESIBA® SHOWED AN OVERALL LOWER RISK OF HYPOGLYCAEMIA AND SIGNIFICANTLY LOWER HBA1C WHEN COMPARED TO INSULIN GLARGINE U300 IN PEOPLE WITH TYPE 2 DIABETES.PRIMARY ENDPOINT, RATE OF OVERALL SYMPTOMATIC HYPOGLYCAEMIA IN MAINTENANCE PERIOD OF 36 WEEKS WHICH WAS TESTED FOR SUPERIORITY, WAS NUMERICALLY LOWER BUT NOT STATISTICALLY SIGNIFICANT VERSUS INSULIN GLARGINE U300.IN THIS HEAD-TO-HEAD TRIAL, TRESIBA® SIGNIFICANTLY REDUCED RATE OF SEVERE HYPOGLYCAEMIA BY 80% AND NOCTURNAL SYMPTOMATIC HYPOGLYCAEMIA BY 37% WHEN COMPARED WITH INSULIN GLARGINE U300 DURING MAINTENANCE PERIOD, AND BY 62% AND 43% RESPECTIVELY IN TOTAL TREATMENT PERIOD WHEN COMPARED WITH INSULIN GLARGINE U300.RATE OF OVERALL SYMPTOMATIC HYPOGLYCAEMIA WAS STATISTICALLY SIGNIFICANTLY LOWER IN FAVOUR OF TRESIBA® DURING TOTAL TREATMENT PERIOD OF UP TO 88 WEEKS.  Full Article

Medtronic Says Co, Novo Nordisk Agred To Provide Integrated Digital Solutions For People With Diabetes
Monday, 16 Sep 2019 

Sept 16 (Reuters) - Medtronic Plc ::MEDTRONIC AND NOVO NORDISK ENTER AGREEMENT TO PROVIDE INTEGRATED DIGITAL SOLUTIONS FOR PEOPLE WITH DIABETES.COLLABORATION TO DEVELOP SOLUTIONS TO INTEGRATE INSULIN DOSING DATA FROM FUTURE NOVO NORDISK SMART INSULIN PENS INTO CGM DEVICES FROM CO.  Full Article

Novo Nordisk Fiasp Approved In Europe
Thursday, 22 Aug 2019 

Aug 22 (Reuters) - Novo Nordisk A/S ::FIASP® APPROVED IN EUROPE FOR MANAGEMENT OF DIABETES IN ADOLESCENTS AND CHILDREN AGED ONE YEAR AND ABOVE.EUROPEAN COMMISSION HAS GRANTED AN EXTENSION OF THE INDICATION FOR FIASP® (FAST-ACTING INSULIN ASPART), APPROVING IT FOR THE TREATMENT OF DIABETES IN ADOLESCENTS AND CHILDREN (AGED ONE YEAR AND ABOVE).THIS COMPLEMENTS THE PREVIOUS INDICATION, WHICH COVERED ADULTS ONLY.  Full Article

Novo Nordisk H1 Operating Profit At DKK 27.69 Bln, Above Estimates
Friday, 9 Aug 2019 

Aug 9 (Reuters) - Novo Nordisk A/S ::REG-NOVO NORDISK'S OPERATING PROFIT INCREASED BY 12% IN DANISH KRONER AND BY 6% AT CONSTANT EXCHANGE RATES (CER) IN THE FIRST SIX MONTHS OF 2019.H1 SALES 59.33 BILLION DKK VERSUS 58.72 BILLION DKK SEEN IN REFINITIV POLL.H1 SALES OF OZEMPIC(®) WERE DKK 3,750 MILLION AND IT HAS NOW BEEN LAUNCHED IN 21 COUNTRIES..SEES 219 SALES GROWTH 4-6% VERSUS PREVIOUSLY 2-5% AT CER.H1 OPERATING PROFIT 27.69 BILLION DKK VERSUS 27.21 BILLION DKK SEEN IN REFINITIV POLL.IN USA, NEW-TO-BRAND PRESCRIPTION MARKET SHARE FOR OZEMPIC(®) IS NOW 35%, BRINGING NOVO NORDISK'S COMBINED GLP-1 NEW-TO-BRAND PRESCRIPTION MARKET SHARE TO 53%.SEES 2019 OPERATING PROFIT GROWTH 4-6% VERSUS PREVIOUSLY 2-6% AT CER.CEO SAYS WE ARE PLEASED WITH SALES GROWTH IN FIRST HALF OF 2019, WHICH IS DRIVEN BY ALL REGIONS IN INTERNATIONAL OPERATIONS.LAUNCH OF OZEMPIC(®) IS EXPANDING GLP-1 MARKET, AND WE ARE ENCOURAGED BY POSITIVE MARKET RECEPTION IN BOTH NORTH AMERICA AND EUROPE..WE CONTINUE TO INVESTIGATE CLINICAL BENEFITS OF SEMAGLUTIDE ACROSS MULTIPLE INDICATIONS.SALES OF GLP-1 PRODUCTS FOR TYPE 2 DIABETES (VICTOZA® AND OZEMPIC® ) INCREASED BY 24% MEASURED IN DANISH KRONER AND BY 18% AT CER TO DKK 14,887 MILLION..H1 VICTOZA SALES DKK 11.14 BILLION.H1 SALES IN NORTH AMERICA OPERATIONS INCREASED BY 5% MEASURED IN DANISH KRONER AND DECREASED BY 2% AT CER..  Full Article

FDA Approves New Treatment For Pediatric Patients With Type 2 Diabetes
Tuesday, 18 Jun 2019 

June 17 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES NEW TREATMENT FOR PEDIATRIC PATIENTS WITH TYPE 2 DIABETES.U.S. FDA - APPROVED VICTOZA (LIRAGLUTIDE) INJECTION FOR TREATMENT OF PEDIATRIC PATIENTS 10 YEARS OR OLDER WITH TYPE 2 DIABETES.FDA - APPROVAL OF VICTOZA WAS GRANTED TO NOVO NORDISK.U.S. FDA - PRESCRIBING INFORMATION FOR VICTOZA INCLUDES BOXED WARNING TO ADVISE ABOUT INCREASED RISK OF THYROID C-CELL TUMORS.  Full Article

Photo

European shares end week on cheery note after U.S. and Chinese data

European shares clocked their best day in over a week on Friday, as upbeat jobs data from the United States and a surprise bounce in Chinese manufacturing tempered nerves around slowing global growth. | Video